| Bioactivity | Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity[1][2]. |
| Target | Interaction between FcRn and IgG |
| Invitro | Orilanolimab (10nM、50nM和100nM；48小时) 抑制 B2MTG/TGFCGRTTG/TGFcgrt-/- 小鼠的 CD11c＜sup＞+ |
| In Vivo | Orilanolimab (20mg/kg；静脉注射) 显著降低小鼠模型中HuLys11的血浆浓度[1]。Orilanolimab (10-100 mg/kg；静脉注射；每5周一次) 导致IgG食蟹猴总循环水平的剂量依赖性和特异性降低[1]。 |
| Name | Orilanolimab |
| CAS | 2066544-85-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Blumberg LJ, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv. 2019 Dec 18;5(12):eaax9586. [2]. Blumberg L, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases[J]. Blood, 2017, 130: 3483. |